Telehealth company Hims & Hers is facing a growing number of U.S. investor lawsuits after Novo Nordisk's decision last month ...

HIMS stock up 16% on Wednesday, continuing month-long gains. Novo Nordisk ends partnership, cites misleading marketing and ...

Hims & Hers Health partnered with Novo Nordisk earlier this year, only for that to unravel shortly afterward due to ...

Novo Nordisk ended a short-lived agreement to sell its Wegovy weight-loss drug through Hims & Hers Health on Monday, sending shares of the U.S. telehealth company plunging more than 30%.

Telehealth platform Hims & Hers Health (NYSE:HIMS) shot to the top of stock charts yesterday as shares soared 16% high on no company news. While it is revolutionizing access to healthcare by ...

This morning, the Danish pharmaceutical giant Novo Nordisk announced the abrupt end of its brief partnership with telehealth company Hims & Hers Health (NYSE: HIMS), citing concerns over Hims & Hers’ ...

San Francisco telehealth company Hims & Hers saw its stock plunge more than 30% earlier this week after a partnership with ...

On April 29, Novo Nordisk (NYSE: NVO) and Hims & Hers Health (NYSE: HIMS) announced they were collaborating to allow Hims & Hers to sell the weight-loss drug Wegovy. Hims & Hers stock soared on ...

Novo Nordisk has ended a partnership with telehealth company Him & Hers, after launching the collaboration less than two months ago.

Hims & Hers stock plunged 35% on Monday after its collaboration with Novo Nordisk came to a halt. The Danish pharmaceutical giant said it was ending the partnership because Hims is selling and ...

HIM & NVO Stock Performance Overview. With the initial announcement of the Novo Nordisk partnership causing a surge in Hims & Hers stock, HIM shares have now soared over +30% in 2025.

Medical pioneers Hims & Hers Health HIMS and Novo Nordisk NVO are making headlines this week after announcing a partnership to expand obesity care in the telehealth space.. The long-term ...